Tonix製藥控股 TNXP 深 滬
等待開盤 08-14 09:30:00 美东时间
61.57
+1.810
+3.03%
華盛通- 最 高63.9999
- 今 開60.32
- 成交量 186.30万股
- 最 低 58.6081
- 昨 收 59.76
- 總市值 115.07亿
- 52周最高 130.00
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 6.76
- 委 比 -38.90%
- 總股本 1.87亿
- 歷史最高 13440000000.00
- 量 比 1.24
- 振 幅 9.02%
- 歷史最低 15.00
- 每 手 1
- 風險率 5.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股盘前 | 美股加密货币概念走强，DFDV大涨超17%；CoreWeave绩后跌超8%
美股加密货币概念走强，DFDV大涨超17%， BMNR涨约2%；CoreWeave绩后跌超8%，公司财报不及预期；Circle跌近5%，公司及创始人宣布抛售1000万股股票>>
08-13 16:45
美股牛股 | 多只绩优股狂飙！Rumbleon涨超60%，Tonix制药控股涨超32%
多只绩优股狂飙！Rumbleon涨超60%，Tonix制药控股涨超32%；美国7月机票价格创3年多来最大月度涨幅！美国航空股Frontier Group涨近30%>>
08-13 15:56
Tonix Pharmaceuticals (TNXP) Stock Surges On Q2 Earnings Beat And Upcoming FDA Catalyst
Shares of Tonix Pharmaceuticals are trading sharply higher Tuesday morning. The stock is gaining following the release of the company's Q2 financial results and operational update.
08-12 23:55
Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights
Tonix Pharmaceuticals announced positive updates on its investigational drug TNX-102 SL for fibromyalgia, with an FDA PDUFA goal date of August 15, 2025. If approved, TNX-102 SL would be the first new treatment for fibromyalgia in over 16 years. The company reported $125.3 million in cash as of June 30, 2025,预计到2026年第三季度。The Phase 3 RESILIENT trial results, published in Pain Medicine, showed significant pain reduction and tolerability. Tonix also...
08-11 20:15
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
NetworkNewsWire Editorial Coverage NEW YORK, Aug. 6, 2025 /PRNewswire/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, partic...
08-06 20:30
Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia
Tonix Pharmaceuticals launched the "Move Fibro Forward" campaign to raise awareness for fibromyalgia, a chronic pain condition with no new FDA-approved treatments in over 15 years. The campaign aims to support individuals impacted by the disease and highlight their experiences. Fibromyalgia affects approximately 10 million adults in the U.S., causing widespread pain, fatigue, and impaired quality of life. Tonix is a biotech company focused on pai...
07-21 11:00
Tonix Pharma Unveils Promising TNX-801 Vaccine Findings
Tonix Pharma ( ($TNXP) ) has provided an update. On July 10, 2025, Tonix Pharma...
07-10 19:28
Tonix Pharma Publishes Phase 3 Trial Results
Tonix Pharma ( ($TNXP) ) just unveiled an announcement. On July 9, 2025, Tonix ...
07-10 04:52
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine
Tonix Pharmaceuticals announced the publication of full results from its Phase 3 RESILIENT trial, showing that TNX-102 SL significantly reduced fibromyalgia pain compared to placebo, confirming prior RELIEF trial results. The drug, a non-opioid analgesic, was generally well-tolerated with mild side effects. The FDA has set an August 15, 2025 PDUFA date for review, and if approved, TNX-102 SL would be the first new fibromyalgia treatment in over 1...
07-09 20:01
